ipamorelin peptide therapy in katy tx CJC-1295 Houston CJC-1295 & Ipamorelin Therapy in

2010 Mar;24(3):653-61

This article is for general educational purposes and is not a substitute for an in-person medical evaluation, diagnosis, or treatment

doi: 10.3389/fphar.2024.1412245 Received 04 April 2024 Accepted 24 June 2024 Published 18 July 2024 Volume 15 - 2024 Edited by Irina Ielciu, University of Medicine and Pharmacy Iuliu Hatieganu, Romania Reviewed by Javad Mottaghipisheh, Swedish University of Agricultural Sciences, Sweden Shaymaa Mahmoud, University of Menoufia, Egypt Ufuk Koca alilkan, Gazi University, Trkiye Aida Abd El-Wahed, Agricultural Research Center, Egypt Gandhi Radis Baptista, Federal University of Ceara, Brazil Updates Copyright 2024 Sadek, Shib, Taher, Rashed, Shukry, Atia, Taymour, El-Nablaway, Ibrahim, Ramadan, Abdelkader, Abdo, Imbrea, Pet, Ali and Abdeen

Ipamorelin currently lacks FDA approval and remains a research peptide that has no approved medical uses